Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 6,313 shares, a decline of 46.2% from the August 15th total of 11,736 shares. Based on an average daily volume of 2,072 shares, the short-interest ratio is presently 3.0 days.
Oculis Price Performance
NASDAQ:OCSAW traded up $0.13 during trading hours on Wednesday, reaching $3.14. 5,018 shares of the company traded hands, compared to its average volume of 5,417. The firm’s 50-day moving average is $4.48 and its 200-day moving average is $9.95. Oculis has a 1-year low of $2.71 and a 1-year high of $22.64.
Oculis Company Profile
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Featured Stories
- Five stocks we like better than Oculis
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
